vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and Sunlands Technology Group (STG). Click either name above to swap in a different company.
Coherus Oncology, Inc. is the larger business by last-quarter revenue ($12.7M vs $10.1M, roughly 1.3× Sunlands Technology Group). Sunlands Technology Group runs the higher net margin — 24.0% vs -295.3%, a 319.3% gap on every dollar of revenue. Over the past eight quarters, Sunlands Technology Group's revenue compounded faster (0.6% CAGR vs -47.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.
CHRS vs STG — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $10.1M |
| Net Profit | $-37.6M | $2.4M |
| Gross Margin | 68.3% | 88.5% |
| Operating Margin | -359.9% | 26.5% |
| Net Margin | -295.3% | 24.0% |
| Revenue YoY | 64.9% | — |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $-0.34 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | — | ||
| Q3 25 | $11.6M | $10.1M | ||
| Q2 25 | $10.3M | $9.3M | ||
| Q4 24 | — | $9.7M | ||
| Q2 24 | $10.3M | $10.0M | ||
| Q3 23 | $74.6M | $9.9M | ||
| Q2 23 | $58.7M | $10.0M | ||
| Q1 23 | $32.4M | — |
| Q4 25 | $-37.6M | — | ||
| Q3 25 | $-35.5M | $2.4M | ||
| Q2 25 | $297.8M | $1.4M | ||
| Q4 24 | — | $1.8M | ||
| Q2 24 | $-12.9M | $2.2M | ||
| Q3 23 | $-39.6M | $2.5M | ||
| Q2 23 | $-42.9M | $3.3M | ||
| Q1 23 | $-75.7M | — |
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | 88.5% | ||
| Q2 25 | 66.9% | 85.2% | ||
| Q4 24 | — | 83.3% | ||
| Q2 24 | 82.4% | 85.2% | ||
| Q3 23 | 56.1% | 87.8% | ||
| Q2 23 | 57.7% | 88.7% | ||
| Q1 23 | 48.0% | — |
| Q4 25 | -359.9% | — | ||
| Q3 25 | -383.1% | 26.5% | ||
| Q2 25 | -443.6% | 15.2% | ||
| Q4 24 | — | 13.4% | ||
| Q2 24 | -384.9% | — | ||
| Q3 23 | -42.9% | 23.3% | ||
| Q2 23 | -58.8% | 29.6% | ||
| Q1 23 | -208.9% | — |
| Q4 25 | -295.3% | — | ||
| Q3 25 | -307.1% | 24.0% | ||
| Q2 25 | 2903.9% | 15.4% | ||
| Q4 24 | — | 18.2% | ||
| Q2 24 | -125.5% | 21.5% | ||
| Q3 23 | -53.2% | 25.1% | ||
| Q2 23 | -73.0% | 33.0% | ||
| Q1 23 | -233.5% | — |
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.31 | — | ||
| Q2 25 | $2.57 | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $-0.11 | $0.31 | ||
| Q3 23 | $-0.41 | — | ||
| Q2 23 | $-0.49 | — | ||
| Q1 23 | $-0.96 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $15.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $17.7M |
| Total Assets | $258.3M | $41.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | — | ||
| Q3 25 | $191.7M | $15.1M | ||
| Q2 25 | $237.6M | — | ||
| Q4 24 | — | $15.6M | ||
| Q2 24 | $159.2M | $18.7M | ||
| Q3 23 | $131.1M | $16.5M | ||
| Q2 23 | $144.7M | — | ||
| Q1 23 | $128.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | $1.5M | ||
| Q2 24 | — | $1.8M | ||
| Q3 23 | — | $2.2M | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
| Q4 25 | $61.0M | — | ||
| Q3 25 | $87.8M | $17.7M | ||
| Q2 25 | $119.8M | $12.6M | ||
| Q4 24 | — | $10.7M | ||
| Q2 24 | $-84.1M | $7.6M | ||
| Q3 23 | $-133.6M | $2.5M | ||
| Q2 23 | $-174.8M | — | ||
| Q1 23 | $-196.5M | — |
| Q4 25 | $258.3M | — | ||
| Q3 25 | $516.5M | $41.2M | ||
| Q2 25 | $439.5M | $40.3M | ||
| Q4 24 | — | $42.4M | ||
| Q2 24 | $674.9M | $41.3M | ||
| Q3 23 | $583.8M | $40.0M | ||
| Q2 23 | $469.6M | — | ||
| Q1 23 | $402.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | 0.14× | ||
| Q2 24 | — | 0.24× | ||
| Q3 23 | — | 0.86× | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | — | ||
| Q3 25 | $-46.3M | — | ||
| Q2 25 | $-46.6M | — | ||
| Q4 24 | — | — | ||
| Q2 24 | $59.7M | — | ||
| Q3 23 | $-54.3M | — | ||
| Q2 23 | $-38.9M | — | ||
| Q1 23 | $-68.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | $-39.0M | — | ||
| Q1 23 | $-68.9M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | -66.4% | — | ||
| Q1 23 | -212.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.2% | — | ||
| Q1 23 | 0.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q4 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
STG
Segment breakdown not available.
